Intel in talks with large investors for equity boost at discount, CNBC reports
The new funding would be another financial lifeline for Intel, as billions of dollars in investment to expand its contract manufacturing business, which is struggling to compete with Taiwan's TSMC, has strained its balance sheet.
The CNBC report, which cited people familiar with the matter, did not name the potential investors. Intel, whose shares fell 7%, did not respond to a Reuters request for comment.
This could be the second capital injection at a discounted price after SoftBank's investment at $23 per Intel share for a stake of just under 2%.
The company's shares had risen nearly 7% on Tuesday on SoftBank's investment plan and had last week gained more than 23% on reports of the U.S. government taking a stake.
On Tuesday, Commerce Secretary Howard Lutnick said the government wants an equity stake in Intel in exchange for CHIPS Act grants approved by former President Joe Biden's administration.
Intel, which had secured about $8 billion in subsidies to build factories - the largest outlay under the 2022 CHIPS Act- has significantly pared back manufacturing ambitions under new CEO Lip-Bu Tan.
Years of management missteps has left the company with virtually no foothold in the booming artificial intelligence chip industry dominated by Nvidia.
Of late, Intel has been on shaky ground with Washington, with U.S. President Donald Trump meeting Tan last week, after seeking his resignation over "highly conflicted" ties to Chinese firms.
Intel's last fiscal year of positive adjusted free cash flow was 2021 and it recorded an annual loss of $18.8 billion in 2024, its first such loss since 1986.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Nvidia orders halt to H20 chip production after China directive, The Information says
(Reuters) -Nvidia has told some of its component suppliers to suspend production work related to H20, its AI chip tailor-made for the Chinese market, The Information reported on Thursday, citing two people with direct knowledge of the communications. Reuters could not immediately verify the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
mDR's (SGX:Y3D) Earnings Offer More Than Meets The Eye
Despite posting healthy earnings, mDR Limited's (SGX:Y3D ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the shareholders should consider. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. How Do Unusual Items Influence Profit? Importantly, our data indicates that mDR's profit was reduced by S$3.7m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect mDR to produce a higher profit next year, all else being equal. Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of mDR. Our Take On mDR's Profit Performance Unusual items (expenses) detracted from mDR's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that mDR's statutory profit actually understates its earnings potential! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For example, we've found that mDR has 4 warning signs (1 is a bit concerning!) that deserve your attention before going any further with your analysis. Today we've zoomed in on a single data point to better understand the nature of mDR's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Trump administration not eyeing equity in companies that are increasing US investment, WSJ reports
(Reuters) -The Trump administration is considering taking equity stakes in companies receiving funds from the 2022 CHIPS Act but has no plans to seek shares in bigger semiconductor firms that are increasing their U.S. investments, the Wall Street Journal reported on Thursday, citing a government official. The development follows comments made by U.S. Commerce Secretary Howard Lutnick, who on Tuesday said the government is continuing to work on the possibility of taking a 10% stake in troubled chipmaker Intel. However, the administration does not intend to take equity stakes in companies like TSMC, which are ramping up investment, the official told the Journal. Businesses not increasing their commitments may need to offer equity to the government in exchange for subsidies. "The Commerce Department is not looking to take equity from TSMC and Micron," the official told WSJ. TSMC executives have already had discussions about giving back their subsidies if the administration asks to become a shareholder, according to the report. The White House and TSMC did not immediately respond to Reuters' requests for comment. TSMC, which counts Nvidia and Apple as key clients, announced plans for a $100 billion investment in the United States during an event with President Donald Trump at the White House in March. This investment is in addition to $65 billion committed for three manufacturing facilities in the state of Arizona. The U.S. Commerce Department, which oversees the $52.7 billion CHIPS Act, formally known as the CHIPS and Science Act, late last year finalized subsidies of $6.6 billion for TSMC to produce semiconductors in the United States. Besides Intel, Micron, TSMC and Samsung were among the biggest recipients of CHIPS Act funding. In the past, the U.S. government has taken stakes in companies during periods of economic uncertainty to provide financial support and restore confidence. Sign in to access your portfolio
